Meeting
2018 ASCO Annual Meeting
A meta-analysis of randomized controlled trials for efficacy and safety of vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) adjuvant therapy in high-risk renal cell cancer (RCC).
Authors
Irbaz Bin Riaz
Mayo Clinic, Rochester, MN
Irbaz Bin Riaz , Saad Malik , Muhammad Husnain , Qurat Ul Ain Riaz Sipra , Warda Faridi , Farva R. Gondal , Hao Xie , Siddhartha Yadav , Manish Kohli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4567)
DOI
10.1200/JCO.2018.36.15_suppl.4567
Abstract #
4567
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
First Author: Rabbia Siddiqi
Poster
2019 ASCO Annual Meeting
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2018 Genitourinary Cancers Symposium
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of high-risk clear cell renal carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2012 Genitourinary Cancers Symposium
Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
First Author: Christopher J. Richards